Related Experiment Videos
Pharmacokinetics of cefoperazone in newborn infants
Insights
Cefoperazone antibiotic disposition was studied in newborn infants. Pharmacokinetics showed a mean half-life of 6.5 hours, with further research needed for clinical use.
Area of Science:
- Neonatal Pharmacology
- Antibiotic Pharmacokinetics
Background:
- Cefoperazone is a valuable antibiotic for neonatal infections.
- Understanding its disposition in newborns is crucial for safe and effective use.
Purpose of the Study:
- To investigate the pharmacokinetic profile of cefoperazone in newborn infants.
- To determine key parameters like half-life, volume of distribution, and clearance.
Main Methods:
- Ten newborn infants received two intravenous doses of cefoperazone (100 mg/kg) 12 hours apart.
- Blood samples were collected to measure drug concentrations and calculate pharmacokinetic parameters.
Main Results:
- Peak cefoperazone levels were high, with troughs of 60-76 mcg/ml.
- Mean half-life was 6.5 hours, decreasing with increased gestational age and birthweight.
- Volume of distribution and total clearance were consistent across infants.
Conclusions:
- Cefoperazone exhibits predictable pharmacokinetics in newborns.
- Further studies on postnatal age, efficacy, and CSF penetration are required before widespread use.
Abstract:
We studied the disposition of two 100 mg/kg doses of cefoperazone given intravenously 12 hr apart in ten newborn infants. Peak levels were a mean 352 +/- SD 75 and 371 +/- 68 micrograms/ml immediately after the first and second dose, respectively, with corresponding troughs of 60 +/- 10 and 76 +/- 28 mcg/ml 12 hr later. Mean half-life was 6.5 +/- 0.9 hr and decreased with increasing gestational age and birthweight. Steady-state volume of distribution averaged 410 +/- 40 ml/kg and total clearance 0.78 +/- 0.13 ml/min X kg and neither varied with gestational age nor birthweight. No untoward physical or laboratory effects were noted. Additional studies including postnatal age effects on kinetics, efficacy, and cerebrospinal fluid penetrance are necessary prior to widespread use of this potentially valuable antibiotic in newborn infants.